[HTML][HTML] Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression
T Montecchi, G Nannini, D De Tommaso… - Cancer Immunology …, 2024 - Springer
Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression
T Montecchi, G Nannini, D De Tommaso, C Cassioli… - bioRxiv, 2023 - biorxiv.org
Background: The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression
T Montecchi, G Nannini… - Cancer …, 2024 - pubmed.ncbi.nlm.nih.gov
Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression
T Montecchi, G Nannini, D De Tommaso… - CANCER …, 2024 - usiena-air.unisi.it
Background: The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression.
T Montecchi, G Nannini, D De Tommaso… - Cancer Immunology …, 2024 - europepmc.org
Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
[HTML][HTML] Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression
T Montecchi, G Nannini, D De Tommaso… - Cancer Immunology …, 2024 - ncbi.nlm.nih.gov
Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression.
T Montecchi, G Nannini, D De Tommaso… - Cancer Immunology …, 2024 - europepmc.org
Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
[PDF][PDF] Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression
T Montecchi, G Nannini, D De Tommaso… - Cancer Immunology …, 2024 - usiena-air.unisi.it
Background The immunosuppressive tumor microenvironment (TME) of colorectal cancer
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …
(CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence …